Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes.

ABSTRACT:

Objective

In the 2018 ATN framework, Alzheimer's neurodegenerative biomarkers comprised cerebrospinal fluid (CSF) total tau, ¹⁸ F-fluorodeoxyglucose-positron emission tomography, and brain atrophy. We aimed to assess the clinical outcomes of having discordant Alzheimer's neurodegenerative biomarkers.

Methods

A total of 721 non-demented individuals from the Alzheimer's Disease Neuroimaging Initiative database were included and then further categorized into concordant-negative, discordant, and concordant-positive groups. Demographic distributions of the groups were compared. Longitudinal changes in clinical outcomes and risk of conversion were assessed using linear mixed-effects models and multivariate Cox proportional hazard models, respectively.

Results

Dis

SUBMITTER: Guo Y 

PROVIDER: S-EPMC7545611 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature